{"title":"Pain response after palliative-intent radiotherapy for pancreatic cancer: a systematic review.","authors":"Kenji Makita, Yuichi Hiroshima, Keiichi Takehana, Tetsuo Saito, Naoki Nakamura, Takeo Takahashi, Yoshiyuki Shioyama","doi":"10.1007/s10147-026-03163-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To date, no review has specifically focused on palliative-intent radiotherapy (RT) for pancreatic cancer (PC)-related pain. This study aimed to evaluate the pain response after palliative-intent RT for PC-related pain.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted using PubMed, Ichushi-Web, and the Cochrane Library for studies published between 1971 and 2024. Studies in which palliative-intent RT was administered for PC-related pain were included. Extracted Data were independently assessed by three reviewers.</p><p><strong>Results: </strong>Of the 629 studies identified through the database search, 11 met the inclusion criteria. The most frequently used palliative-intent RT schedules were 30 Gy in 10 fractions for conventional RT and 25 Gy in a single fraction for stereotactic body radiotherapy (SBRT). In addition, 8 Gy once weekly (24 Gy in 3 fractions) RT has also been reported. Because the methods used for pain assessment varied across the included studies, a meta-analysis was considered inappropriate. Pain associated with PC improved following palliative-intent conventional RT (pain response rate, 69-94%), palliative-intent SBRT (pain response rate, 53-90%), and 8 Gy once weekly RT (pain response rate, 80%). A few grade ≥ 3 gastrointestinal adverse events were reported (< 10%).</p><p><strong>Conclusion: </strong>Palliative-intent RT appears to be a promising approach for alleviating PC-related pain. However, the current evidence is heterogeneous in terms of target selection and dose-fractionations. Further studies, including randomized controlled trials, may help identify optimal treatment strategies.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2150-2157"},"PeriodicalIF":3.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-026-03163-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To date, no review has specifically focused on palliative-intent radiotherapy (RT) for pancreatic cancer (PC)-related pain. This study aimed to evaluate the pain response after palliative-intent RT for PC-related pain.
Methods: A comprehensive literature search was conducted using PubMed, Ichushi-Web, and the Cochrane Library for studies published between 1971 and 2024. Studies in which palliative-intent RT was administered for PC-related pain were included. Extracted Data were independently assessed by three reviewers.
Results: Of the 629 studies identified through the database search, 11 met the inclusion criteria. The most frequently used palliative-intent RT schedules were 30 Gy in 10 fractions for conventional RT and 25 Gy in a single fraction for stereotactic body radiotherapy (SBRT). In addition, 8 Gy once weekly (24 Gy in 3 fractions) RT has also been reported. Because the methods used for pain assessment varied across the included studies, a meta-analysis was considered inappropriate. Pain associated with PC improved following palliative-intent conventional RT (pain response rate, 69-94%), palliative-intent SBRT (pain response rate, 53-90%), and 8 Gy once weekly RT (pain response rate, 80%). A few grade ≥ 3 gastrointestinal adverse events were reported (< 10%).
Conclusion: Palliative-intent RT appears to be a promising approach for alleviating PC-related pain. However, the current evidence is heterogeneous in terms of target selection and dose-fractionations. Further studies, including randomized controlled trials, may help identify optimal treatment strategies.
期刊介绍:
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.